Drug intelligence / Profile preview

SOL101

Development stage: Preclinical
Lead developer: Shine-On Biomedical

Overview

SOL101 is an experimental drug candidate currently under development by Shine-On BioMedical. It is part of a 'limited experimental program' within the company's pipeline, with specific details regarding its molecular modality and mechanism of action not yet publicly disclosed. The program is exploring the therapeutic potential of SOL101 across a diverse range of indications, including glioma syndrome, Sjögren's syndrome, and dry age-related macular degeneration (dry AMD). Based on available pipeline data, the candidate is in the preclinical stage of development and belongs to the 'SOL' series of programs, which also encompasses immune rejuvenation and over-the-counter (OTC) product platforms.

Targets

RPS6KB1 (Ribosomal protein S6 kinase beta-1)

Beyond the preview

Go deeper on SOL101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL101.

Explore the full profile